pentylenetetrazole
Pentetrazol (pentylenetetrazole, BTD-001) is a pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive gamma-aminobutyric acid (GABA) antagonist. Pentetrazol (pentylenetetrazole) has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility. GABA is thought to play a role in promoting sleep and its function is believed to be elevated in idiopathic hypersomnia. By blocking GABA’s function, pentetrazol (pentylenetetrazole, BTD-001) is expected to reduce excessive daytime sleepiness. — NCATS
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started Sep 1, 2015 (NCT02512588)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
SMILES
C1CCN2N=NN=C2CC1- Mol. weight
- 138.1704 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPentylenetetrazol ↗
- NCATSWM5Z385K7T ↗
Also known as
- 1,5-pentamethylenetetrazole
- btd-001
- cardiazole
- leptazol
- pentamethazol
- pentazol
- pentetrazol
- pentetrazol
- pentetrazol
- pentylenetetrazole
- pentylenetetrazole
- pentylenetetrazole
- pentylenetetrazole
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03542851 | Phase 2 | May 29, 2018 | Balance Therapeutics |
| NCT03150498 | Phase 1 | May 3, 2017 | Balance Therapeutics, Quotient |
| NCT03107013 | Phase 1 | Apr 3, 2017 | Balance Therapeutics, Quotient |
| NCT02512588 | Phase 2 | Sep 1, 2015 | Balance Therapeutics |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Balance Therapeutics | For profit | 4 | 4 | 2 | 2015 |
| Quotient | For profit | 2 | 0 | 1 | 2017 |